·Week of July 27-31, 2026

Clinical Trials Brief | August 3, 2026

This week: Health Canada setting trial registration and results-disclosure expectations and launching a new public trial portal, FDA finalising three guidances to broaden cancer trial eligibility, the EU authorising XFG-adapted COVID-19 vaccines within a week of CHMP's opinion, the MHRA adding an overlap syndrome warning to checkpoint inhibitors, and two back-to-back FDA advisory committees showing how statistical analysis plan changes can decide an application.

Health Canada sets trial registration and results-disclosure expectations, a step toward mandatory transparency

What changed

On July 29, 2026, Health Canada published its final Guidance on the Registration of Clinical Trials and Public Disclosure of Results and launched a new Clinical Trial Search Portal, replacing the Clinical Trials Database it introduced in 2013. The guidance covers sponsors of trials regulated under the Food and Drugs Act, including Phase 1 to 3 drug and natural health product trials and investigational testing of Class II to IV devices. Registration should take place in a WHO-compliant registry before enrolment opens and no later than 21 calendar days after the first participant is enrolled. Summary results should be posted within 12 months of primary study completion. Citeline reports that comparative bioavailability studies, single-patient trials and Phase 4 trials within approved conditions are excluded, and that the final text introduces a new results deferral. The guidance is not legally binding, but Health Canada presents it as preparation for future regulations that would make registration and results reporting mandatory.

Why it matters

This moves Canada closer to the EU Clinical Trials Regulation, the UK's amended regulations and US ClinicalTrials.gov requirements. Health Canada has said the portal will flag authorised trials it cannot match to a registry record, so gaps in sponsor registration will become publicly visible, which is a form of enforcement even without legal force. Because Health Canada uses international registries rather than its own, sponsors' existing ClinicalTrials.gov or EU CTIS records will usually be what the portal displays.

Takeaway

Sponsors with Canadian sites should check that every Health Canada-authorised trial has a registry record that the portal can match, ideally with the Canadian authorisation reflected, and that results-posting timelines in their disclosure SOPs cover the 12-month expectation for Canada as well.

Sources

This item is grounded in Health Canada's guidance pages and analysis by McCarthy Tétrault, Fasken, Emergo by UL and Citeline.

FDA finalises three guidances to broaden cancer trial eligibility, with performance status 2 now expected to be included

What changed

On July 27, 2026, FDA's Oncology Center of Excellence, with CDER and CBER, finalised three guidances on cancer clinical trial eligibility criteria: Performance Status; Laboratory Values; and Washout Periods and Concomitant Medications. They were announced in the Federal Register on July 28. All three are addressed to industry, IRBs and clinical investigators. According to CASRAI's summary, FDA says patients with ECOG performance status 2 should be included, baseline performance status should be collected in all trials and can be used as a stratification factor, and laboratory-value restrictions from earlier trials should not be carried forward automatically. The lab-values guidance recommends criteria that protect participants without unnecessarily excluding patients.

Why it matters

Restrictive eligibility criteria are one of the main reasons oncology trial populations look healthier than real-world patients, which limits how well results apply in practice and slows enrolment. Addressing the guidances to IRBs as well as sponsors matters, because ethics committees often push for conservative criteria. Finalising these alongside the June substantial-evidence draft, which asks whether trial populations reflect US clinical practice, gives sponsors a consistent message: broader eligibility is part of evidentiary strength, not just a diversity goal.

Takeaway

Oncology protocol teams should review inclusion and exclusion criteria line by line against the three final guidances, especially inherited lab cut-offs and washout periods copied from earlier studies. Where narrower criteria are retained, the protocol should explain why.

Sources

This item is grounded in FDA's guidance listings and the CASRAI and Caidya summaries of the July 27, 2026 final guidances.

The EU authorises XFG-adapted COVID-19 vaccines within a week of CHMP's opinion, on immunogenicity and quality data

What changed

On July 29, 2026, Pfizer and BioNTech announced that the European Commission had authorised their 2026-2027 COVID-19 vaccine targeting the XFG variant for people aged 6 months and older. The decision followed CHMP's positive opinion of July 23, which also covered XFG-adapted versions of Bimervax, Nuvaxovid and Spikevax, in line with the strain recommendation from EMA's Emergency Task Force for the 2026/2027 campaign. According to the companies, the authorisation rests on the cumulative clinical evidence for earlier versions of the vaccine plus manufacturing, quality and nonclinical data showing strong immune responses against currently circulating lineages. Manufacturing had already started at risk.

Why it matters

This is the strain-update model working as designed: once a platform's safety and efficacy are established, annual composition changes are approved on immunogenicity and quality data rather than new efficacy trials, much like seasonal flu vaccines. The speed, about a week from CHMP opinion to Commission decision, shows how this approach supports seasonal preparedness.

Takeaway

For vaccine sponsors, the EU process rewards a well-maintained cumulative evidence base and early manufacturing readiness. For clinical operations, strain-update cycles mean any ongoing vaccine trial using a licensed COVID-19 vaccine as comparator or background should check which formulation sites will actually receive this season.

Sources

This item is grounded in the Pfizer-BioNTech announcement of July 29, 2026 and EMA's CHMP highlights of July 24, 2026.

MHRA adds myocarditis-myositis-myasthenia gravis overlap syndrome to checkpoint inhibitor labels and warns on iatrogenic botulism

What changed

The MHRA's July 2026 Safety Roundup, published July 30, reported several updates. The product information for avelumab, ipilimumab, nivolumab, nivolumab with relatlimab, and pembrolizumab now includes myocarditis-myositis-myasthenia gravis overlap syndrome, where two or all three conditions occur together. This carries a high risk of morbidity and death, and the labels now include advice on when to withhold or permanently stop treatment. A Drug Safety Update warns of rare iatrogenic botulism after therapeutic or cosmetic botulinum toxin use. Symptoms typically appear 4 to 8 days after treatment but can take up to 4 weeks, with higher risk linked to high doses, off-label sites and counterfeit products. Domperidone is now contraindicated in confirmed or suspected phaeochromocytoma because of severe hypertension. A review of bladder anticholinergics concluded that the evidence is not sufficient to confirm that they directly increase dementia risk, although a small increased risk cannot be ruled out.

Why it matters

The checkpoint inhibitor change is the most relevant for clinical trials. Immune-mediated myocarditis, myositis and myasthenia gravis are each known risks, but treating them as an overlap syndrome changes what investigators should look for. A patient presenting with muscle weakness may also have cardiac involvement that is not yet symptomatic. The MHRA stresses early recognition and aggressive management. With checkpoint inhibitors used as backbone or comparator in a large share of oncology trials, the labelling change affects many protocols at once.

Takeaway

Sponsors of checkpoint inhibitor trials should check that investigator brochures, protocol toxicity-management sections and site training cover the overlap syndrome, including baseline and on-treatment troponin and CK monitoring where appropriate. Medical monitors should review any single myositis, myocarditis or myasthenia event for signs of the others.

Sources

This item is grounded in the MHRA Safety Roundup for July 2026, published July 30.

Two back-to-back FDA advisory committees show how statistical analysis plan changes can decide an application

What changed

On July 29 and 30, 2026, FDA's Cellular, Tissue, and Gene Therapies Advisory Committee met on two resubmitted applications. On July 29, it voted 9-3 that the evidence did not show substantial effectiveness for Capricor's deramiocel in treating cardiomyopathy in Duchenne muscular dystrophy. FDA's briefing documents said the Phase 3 HOPE-3 trial did not meet its prespecified primary and secondary endpoints. Reuters reported that FDA staff questioned changes to key analyses made after the study was completed, including switching the arm-function analysis to percentage change and the cardiac measure to a ranked outcome. Capricor's results under its later analysis plan were published in The Lancet the same day. On July 30, the committee voted 10-3 that efficacy results from Replimune's single-arm IGNYTE study of RP1 in melanoma were evaluable and clinically meaningful, despite FDA staff concerns. Both votes are non-binding. Deramiocel's action date is August 22.

Why it matters

The deramiocel meeting is a case study in analysis-plan governance. According to the FDA Law Blog, the disagreement turned largely on which version of the statistical analysis plan should apply, and FDA effectively declined to accept changes made after the trial was completed. For anyone working in data management or biostatistics, the lesson is the timing and documentation of SAP amendments relative to unblinding, not the statistics.

Takeaway

Finalise and version-control the SAP before database lock and unblinding. Document the rationale for every amendment, along with evidence of who had access to unblinded data, and discuss material changes with FDA in advance. A peer-reviewed publication does not substitute for a prespecified analysis that regulators accept.

Sources

This item is grounded in Capricor's SEC filing of July 29-30, 2026, reporting by NeurologyLive and Reuters, and FDA Law Blog analysis (published August 5, 2026).

Clinical Trials Brief is an educational commentary archive, not a real-time news service. Confirmed facts are based on publicly cited sources where possible. Analytical comments, comparisons, and forward-looking views are personal interpretation unless otherwise stated.